ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

• Solid Form Strategies For Increasing Oral Bioavailability

  Optimizing a drug’s solid form can improve its solubility and bioavailability when further molecular modifications are prohibitive.

• Simultaneous Spray Drying For Combination Dry Powder Inhaler Formulations

  Three combination case studies are demonstrated, in which bevacizumab is paired with erlotinib, cisplatin, or paclitaxel in a dry powder inhaler formulation.

• Closing The Duration Gap In FDA-Approved Long-Acting Contraceptives

  A gap exists between three months and three years in FDA-approved long-acting contraceptives (LACs). A microsphere formulation enables sustained release over a six to twelve-month period.

• Selecting A Strategic Partner For Your Combination Product

  It is imperative to choose an experienced partner that can ensure the highest quality products, minimize supply chain disruptions, and efficiently bring safe, effective drug products to patients.

• Nanoformed API: A Superior Alternative To Solid Dispersions

  Cutting-edge nanotechnology is now emerging, able to address bioavailability challenges and deliver higher drug loads in more patient-friendly formats with fewer and smaller pills and easier regimens.

• Is Your Combination Product Drug-Led Or Device-Led?

  The $118 billion combination-product market is projected to increase at a CAGR of 8.8%. This article answers the question: “Is this actually a combination product? What do we need to do if it is?”

• Delivering The Promise Of Gene Therapy

  Gene therapies rely on efficient, precise methods of delivering genetic material. Examine how combining polymeric nanoparticles with CRISPR therapies is increasing the potential for improved treatment.

• Zero-Stress Low Volume Aseptic Filling For Solids And Liquids

  Aseptic filling technology is of utmost importance. Explore in great detail an aseptic filling solution that has been specifically designed for laboratory and R&D applications in the pharmaceutical industry.

• Safeguarding Cell Therapy Cryopreservation: Primary Containers

  Review different aspects of container selection from the perspective of cryopreservation that are may be overlooked but critical for the quality of cell therapy drug products.

• Achieving EU GMP Annex 1 Compliance For Contamination Control

  Gain insight into three areas that have been key in ensuring a robust contamination control strategy to help ensure compliance with the updated Annex 1 regulation: planning, people, and products.